Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | APOB | P04114 | 2/20 | 0.46 |
| ▸ | MTTP | P55157 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488310 | 0.94 | SMN1; SMN2 (0.51) | SMN1; SMN2TP53LMNAAPOBMTTP | |
| SCHEMBL6502572 | 0.93 | SMN1; SMN2 (0.60) | SMN1; SMN2TP53RAB9AOPRL1POLB | |
| SCHEMBL6489479 | 0.92 | TP53 (0.47) | SMN1; SMN2TP53LMNAAPOBMTTP | |
| SCHEMBL6492199 | 0.90 | TP53 (0.46) | TP53LMNAAPOBMTTPRAB9A | |
| SCHEMBL6501928 | 0.89 | SMN1; SMN2 (0.53) | SMN1; SMN2TP53LMNARAB9AOPRL1 | |
| SCHEMBL6499252 | 0.88 | POLB (0.47) | SMN1; SMN2TP53LMNAAPOBMTTP | |
| SCHEMBL6800702 | 0.88 | RAB9A (0.47) | SMN1; SMN2TP53LMNAAPOBMTTP | |
| SCHEMBL6499275 | 0.86 | MTTP (0.47) | APOBMTTPOPRL1MCHR1 | |
| SCHEMBL6501410 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2TP53RAB9AOPRL1POLB | |
| SCHEMBL6499318 | 0.84 | MAPT (0.49) | SMN1; SMN2TP53RAB9APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMN1; SMN2 1921/4885TP53 3031/4885LMNA 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.